Clinical Commander

Back to dossier
cardio.atrial_flutter.amyloidosis-related.v1PRODUCTION
cardio.atrial_flutter.amyloidosis-related.v1

Atrial flutter in cardiac amyloidosis (ATTR-CM and AL)

cardiologyacutechronicadult
Hard-required inputs
0 / 16
Care setting:

Encounter flow

12/12 authored

Canonical 12-phase frame with authored status for this dossier.

Current phase

Frame

Detailed

Atrial flutter in cardiac amyloidosis — three-axis decision: (1) amyloid type (AL vs ATTRwt vs ATTRv) drives disease-modifying therapy; (2) AFL management with AMYLOID-SPECIFIC AVOID list (digoxin contraindicated, BB poorly tolerated, diltiazem cautious); (3) AC strategy (lifelong DOAC, lower CHA2DS2-VASc threshold per Kittleson 2023, TEE mandatory pre-CV). ESC 2023 amyloidosis (PMID 37596926) + ACC/AHA 2024 AF (PMID 38753446) + Kittleson 2023 (PMID 37290437)

Inputs
2
Actions
0
Advance rule
Set
Advance when

amyloidosis-related AFL framework established

Patient inputs (19)

MANDATORY before PYP read — rule out AL amyloidosis; difference >18 mg/L abnormal (Mayo AL staging)

Detect monoclonal protein for AL workup (combined sensitivity ~99% with SFLC)

Mandatory before any cardioversion in amyloidosis-AFL — atrial mechanical dysfunction persists in sinus rhythm; LAA thrombus common (~25–30% in amyloid AFL vs ~5–10% in non-amyloid AFL)

TTR PYP scan: visual grade 2–3 + H/CL ratio ≥1.5 + negative monoclonal screen → ATTR diagnosis (no biopsy needed); otherwise endomyocardial biopsy with mass spec for definitive typing

ATTRwt overwhelmingly age >65; AL across ages; ATTRv often presents 30–60 with hereditary mutation; CHA2DS2-VASc + ablation candidacy

AFL RVR severity; rate-control target tighter (preserve preload-dependent cardiac output); avoid bradycardia which crashes CO in restrictive physiology

Cardiorenal common in amyloid; DOAC dose; tafamidis dose unaffected; patisiran requires baseline LFT/eGFR

Critical to identify and DISCONTINUE digoxin if present (absolute contraindication); review BB/CCB tolerance

Markedly elevated in amyloid (often >3000 even with normal LVEF); also a Mayo AL staging variable (>1800)

Persistently elevated in amyloid (myocardial infiltration); Mayo AL stage variable (cTnT >0.025 or hsTnT >40)

Thyrotoxic flutter mimic; reversible cause to exclude before attributing to amyloid

Apical sparing pattern (preserved apical longitudinal strain with reduced basal strain) — amyloid signature; LV wall thickness + restrictive filling + LA dilation + biatrial dysfunction

Confirm AFL morphology + rate; look for amyloid signatures (low voltage in limb leads, pseudo-infarct pattern, conduction delays)

Hypotension highly common in amyloid (autonomic + restrictive); narrow tolerance for AVN blockers + diuretics

CHA2DS2-VASc; in amyloid, many experts anticoagulate even with low CHA2DS2-VASc due to atrial myopathy + intracardiac thrombus risk (Kittleson ACC/AHA 2023 PMID 37290437)

HAS-BLED; amyloid patients often have factor X deficiency (AL) or vascular fragility — heightened bleed risk

Distinguish ATTRwt vs ATTRv after ATTR diagnosis confirmed (drives family screening + gene-silencer eligibility)

V122I ATTR variant prevalent in West African / African-American descent (~3–4%) — drives variant ATTR screen

ATTRv signal — autonomic + peripheral neuropathy + bilateral carpal tunnel

* = hard-required. Engine cannot meaningfully run until these are filled.

Severity triggers (6)

6 need judgement
  • informationallife_threateningdigoxin_toxicity_in_cardiac_amyloidosis
    Patient with cardiac amyloidosis presenting with new bradyarrhythmia, AV block, GI symptoms, visual disturbance, or altered mental status while on digoxin (often initiated outside facility for AFL rate control without amyloid recognition) — life-threatening iatrogenic emergency
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateningal_amyloidosis_oncologic_emergency_with_aflutter
    AL amyloidosis (positive monoclonal screen + biopsy or PYP-negative + cardiac involvement) with rising FLC + cardiac stage III–IV (NT-proBNP >8500 + troponin elevated) presenting with AFL — combined arrhythmic + oncologic emergency
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationallife_threateninghemodynamic_instability_in_amyloid_aflutter_with_restrictive_physiology
    SBP <90 + lactate >2 + amyloid AFL — restrictive low-output state; usually preload depletion (over-diuresis), AVN-blocker excess, or amyloid CS
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverebeta_blocker_intolerance_with_bradyarrhythmia
    BB-induced symptomatic bradycardia, AV block, or worsening orthostasis in amyloid AFL patient (autonomic dysfunction + amyloid AV node sensitivity)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalseverelaa_thrombus_on_pre_cardioversion_tee
    TEE shows LAA thrombus pre-planned cardioversion in amyloid AFL — common finding (25–30% incidence vs 5–10% in non-amyloid AFL)
    Trigger could not be auto-evaluated — needs clinician judgement.
  • informationalmoderateattr_cm_diagnosis_prompting_tafamidis_initiation
    PYP scan grade 2–3 + H/CL ratio ≥1.5 + negative monoclonal screen → ATTR-CM definitively diagnosed in patient previously workup for "unexplained AFL with thick walls" — disease-modifying therapy initiation indicated
    Trigger could not be auto-evaluated — needs clinician judgement.

Workflow calculators

Run this disease's risk and dosing calculators inline.

RISK_STRATIFICATIONrequiredDrives risk stratification
Loading…

Recommended regimen

Atrial flutter in cardiac amyloidosis — amyloid-type phenotype-specific (AL vs ATTRwt vs ATTRv) rate control + AC + disease-modifying pathway with critical drug-class avoidance — ESC 2023 amyloidosis (PMID 37596926) + ACC/AHA 2024 AF (PMID 38753446) + Kittleson 2023 (PMID 37290437) + ATTR-ACT (PMID 30145930)
axis: amyloid_aflutter_phenotype_specific_pathway
Selected axis "Atrial flutter in cardiac amyloidosis — amyloid-type phenotype-specific (AL vs ATTRwt vs ATTRv) rate control + AC + disease-modifying pathway with critical drug-class avoidance — ESC 2023 amyloidosis (PMID 37596926) + ACC/AHA 2024 AF (PMID 38753446) + Kittleson 2023 (PMID 37290437) + ATTR-ACT (PMID 30145930)" by default fallback (first axis)
  • metoprolol_succinate
    first line
    beta_blocker
    LOW DOSE START: 12.5 mg PO daily, titrate q1–2 wk to max tolerated (often 25–50 mg daily ceiling in amyloid); reassess SBP + orthostasis + functional status before each titration • PO • daily
    triggers: amyloid_aflutter_with_RVR_>110, preserved_SBP_>110_no_severe_orthostasis
    AVN slowing for AFL but amyloid patients have narrow tolerance; ESC 2023 (PMID 37596926) acknowledges BB poorly tolerated; many require dose ceilings or discontinuation; Kittleson 2023 (PMID 37290437) recommends individualized cautious approach
    rxcui 866427
  • diltiazem
    second line
    non_DHP_CCB
    CAUTIOUS LOW-DOSE: diltiazem CD 120 mg PO daily start (NOT 240–360 mg); avoid IV unless absolutely necessary; AVOID if EF <40 or SBP <100 • PO • daily
    triggers: BB_intolerant_with_AFL_RVR, EF_preserved_>40, SBP_>100
    AVN slowing alternative; CAUTIOUS — non-DHP CCBs also bind amyloid (less than digoxin) and worsen restrictive failure; ESC 2023 (PMID 37596926) cautions on use; AVOID in HFrEF or significant orthostasis
    rxcui 3443
  • apixaban
    first line
    DOAC_factor_Xa
    5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) • PO • BID
    triggers: amyloid_aflutter_with_AC_indication, CHA2DS2VASc_>=1_in_amyloid_per_Kittleson_2023, pre_post_cardioversion, pre_post_ablation, lifelong_indication
    ARISTOTLE (Granger NEJM 2011 PMID 21870978); preferred DOAC in amyloid given lowest bleed risk profile; Kittleson 2023 (PMID 37290437) — AC even at low CHA2DS2-VASc due to atrial myopathy thrombus risk
    rxcui 1364430
  • rivaroxaban
    first line
    DOAC_factor_Xa
    20 mg with food (15 mg if CrCl 15–50) • PO • once daily
    triggers: amyloid_aflutter_apixaban_unavailable, CHA2DS2VASc_>=1_in_amyloid
    ROCKET-AF (Patel NEJM 2011 PMID 21830957); higher bleed risk than apixaban — second choice in amyloid
    rxcui 1114195
  • edoxaban
    second line
    DOAC_factor_Xa
    60 mg daily (30 mg if CrCl 15–50, ≤60 kg, or P-gp inhibitor); avoid CrCl >95 • PO • once daily
    triggers: amyloid_aflutter_DOAC_alternative
    ENGAGE-AF-TIMI-48 — alternative DOAC
    rxcui 1599538
  • warfarin
    comorbidity specific
    vitamin_K_antagonist
    5 mg daily; INR target 2–3 • PO • daily
    triggers: mechanical_valve, severe_mitral_stenosis, AL_amyloidosis_with_factor_X_deficiency_DOAC_unsafe, severe_renal_failure_CrCl_<15
    Warfarin in AL with factor X deficiency may be safer in select cases (DOAC anti-Xa effect compounds bleeding risk); coordinate with hematology
    rxcui 11289
  • tafamidis
    first line
    ttr_stabilizer
    61 mg PO daily (free acid; equivalent to tafamidis meglumine 80 mg); lifelong • PO • daily lifelong
    triggers: attr_cm_diagnosed_via_PYP_or_biopsy, NYHA_class_1_or_2_attr, NYHA_3_individualized
    ATTR-ACT (Maurer NEJM 2018 PMID 30145930) — 30% all-cause mortality reduction over 30 mo; greatest benefit NYHA I–II; may slow AFL substrate progression by reducing atrial amyloid deposition
    rxcui 1545063
  • patisiran
    add on
    ttr_silencer_sirna
    0.3 mg/kg IV every 3 weeks (premedicate with dex/H1/H2/acetaminophen) • IV • every 3 weeks
    triggers: attrv_cm_with_polyneuropathy, attr_cm_progression_on_tafamidis_alone
    APOLLO (Adams NEJM 2018 PMID 30144829) — siRNA reduces hepatic TTR production
    rxcui 2053490
  • vutrisiran
    add on
    ttr_silencer_sirna
    25 mg SC every 3 months • SC • every 3 months
    triggers: attr_cm_with_polyneuropathy, tafamidis_inadequate_response, patisiran_alternative_for_SC_convenience
    HELIOS-A (Adams Lancet Neurol 2023 PMID 35262029) — SC dosing convenience
    rxcui 2604578
  • daratumumab
    first line
    anti_cd38_monoclonal_antibody
    1800 mg SC weekly × 8, then biweekly × 16, then monthly (with bortezomib + cyclophosphamide + dex — D-VCd regimen) • SC • per ANDROMEDA schedule
    triggers: al_amyloidosis_newly_diagnosed, al_amyloidosis_with_cardiac_involvement_stage_2_or_3a
    ANDROMEDA (Kastritis NEJM 2021 PMID 34077641) — daratumumab + CyBorD improved hematologic CR + organ response in AL; AFL component managed simultaneously
    rxcui 1721947
  • amiodarone
    second line
    class_III_AAD
    150 mg IV over 10 min then 1 mg/min × 6 h then 0.5 mg/min × 18 h; 200 mg PO daily maintenance • IV/PO • load + daily
    triggers: amyloid_aflutter_rhythm_strategy, rate_refractory_AFL_in_amyloid, pre_TEE_guided_cardioversion_pharmacological_facilitation
    Most efficacious AAD in structural heart disease; safer than class IC in amyloid; pulm/thyroid/hepatic toxicity monitoring required; ACC/AHA 2024 (PMID 38753446)
    rxcui 703

outpatient playbook — drug actions (4)

  1. 1. continue lifelong DOAC
    rxcui 1364430
    apixaban 5 mg BID per CHA2DS2-VASc + dose-reduction criteria • PO • BID
    trigger: Lifelong stroke prevention in amyloid AFL
    ARISTOTLE PMID 21870978; Kittleson 2023 lifelong indication
  2. 2. continue tafamidis 61 mg daily
    rxcui 1495093
    61 mg PO daily • PO • daily lifelong
    trigger: ATTR-CM established
    ATTR-ACT (PMID 30145930)
  3. 3. wean rate control if successful CTI ablation (rare success in amyloid)
    rxcui 866427
    taper metoprolol cautiously over 4–8 weeks if no recurrence at 3 mo • PO • taper
    trigger: Successful ablation + no recurrence + tolerating taper
    ACC/AHA 2024
  4. 4. consider gene-silencer add-on for progression
    vutrisiran 25 mg SC every 3 months • SC • q3mo
    trigger: ATTR progression on tafamidis alone (rising NT-proBNP, declining 6MWD, polyneuropathy)
    HELIOS-A (PMID 35262029)

Auto-drafted A&P note

outpatient

Subjective

- Possible entry pathways: Atrial flutter on ECG/telemetry + LV wall thickness ≥12 mm + no long-standing HTN — amyloidosis screen; AFL with low-voltage QRS + thick LV walls (voltage-mass mismatch — amyloid signature); Elderly male with bilateral carpal tunnel release history + new AFL — ATTRwt clue.

Objective

- No vitals, labs, or imaging entered for this encounter.

Assessment

**Atrial flutter in cardiac amyloidosis (ATTR-CM and AL)** (cardio.atrial_flutter.amyloidosis-related.v1).
Phenotype framing: AFL from amyloid vs AFL with coincidental amyloid; AL vs ATTRwt vs ATTRv (drives therapy completely); amyloid vs HOCM vs hypertensive heart vs Fabry vs sarcoidosis (echo + PYP + biopsy)
Scope: Atrial flutter in cardiac amyloidosis — three-axis decision: (1) amyloid type (AL vs ATTRwt vs ATTRv) drives disease-modifying therapy; (2) AFL management with AMYLOID-SPECIFIC AVOID list (digoxin contraindicated, BB poorly tolerated, diltiazem cautious); (3) AC strategy (lifelong DOAC, lower CHA2DS2-VASc threshold per Kittleson 2023, TEE mandatory pre-CV). ESC 2023 amyloidosis (PMID 37596926) + ACC/AHA 2024 AF (PMID 38753446) + Kittleson 2023 (PMID 37290437)

No severity triggers fired against current inputs.

Plan

Regimen axis: **Atrial flutter in cardiac amyloidosis — amyloid-type phenotype-specific (AL vs ATTRwt vs ATTRv) rate control + AC + disease-modifying pathway with critical drug-class avoidance — ESC 2023 amyloidosis (PMID 37596926) + ACC/AHA 2024 AF (PMID 38753446) + Kittleson 2023 (PMID 37290437) + ATTR-ACT (PMID 30145930)**.
1. metoprolol_succinate LOW DOSE START: 12.5 mg PO daily, titrate q1–2 wk to max tolerated (often 25–50 mg daily ceiling in amyloid); reassess SBP + orthostasis + functional status before each titration PO daily (beta_blocker, first line) — AVN slowing for AFL but amyloid patients have narrow tolerance; ESC 2023 (PMID 37596926) acknowledges BB poorly tolerated; many require dose ceilings or discontinuation; Kittleson 2023 (PMID 37290437) recommends individualized cautious approach
2. diltiazem CAUTIOUS LOW-DOSE: diltiazem CD 120 mg PO daily start (NOT 240–360 mg); avoid IV unless absolutely necessary; AVOID if EF <40 or SBP <100 PO daily (non_DHP_CCB, second line) — AVN slowing alternative; CAUTIOUS — non-DHP CCBs also bind amyloid (less than digoxin) and worsen restrictive failure; ESC 2023 (PMID 37596926) cautions on use; AVOID in HFrEF or significant orthostasis
3. apixaban 5 mg BID (2.5 mg BID if 2 of: ≥80 yr, ≤60 kg, Cr ≥1.5) PO BID (DOAC_factor_Xa, first line) — ARISTOTLE (Granger NEJM 2011 PMID 21870978); preferred DOAC in amyloid given lowest bleed risk profile; Kittleson 2023 (PMID 37290437) — AC even at low CHA2DS2-VASc due to atrial myopathy thrombus risk
4. rivaroxaban 20 mg with food (15 mg if CrCl 15–50) PO once daily (DOAC_factor_Xa, first line) — ROCKET-AF (Patel NEJM 2011 PMID 21830957); higher bleed risk than apixaban — second choice in amyloid
5. edoxaban 60 mg daily (30 mg if CrCl 15–50, ≤60 kg, or P-gp inhibitor); avoid CrCl >95 PO once daily (DOAC_factor_Xa, second line) — ENGAGE-AF-TIMI-48 — alternative DOAC
6. warfarin 5 mg daily; INR target 2–3 PO daily (vitamin_K_antagonist, comorbidity specific) — Warfarin in AL with factor X deficiency may be safer in select cases (DOAC anti-Xa effect compounds bleeding risk); coordinate with hematology
7. tafamidis 61 mg PO daily (free acid; equivalent to tafamidis meglumine 80 mg); lifelong PO daily lifelong (ttr_stabilizer, first line) — ATTR-ACT (Maurer NEJM 2018 PMID 30145930) — 30% all-cause mortality reduction over 30 mo; greatest benefit NYHA I–II; may slow AFL substrate progression by reducing atrial amyloid deposition
8. patisiran 0.3 mg/kg IV every 3 weeks (premedicate with dex/H1/H2/acetaminophen) IV every 3 weeks (ttr_silencer_sirna, add on) — APOLLO (Adams NEJM 2018 PMID 30144829) — siRNA reduces hepatic TTR production
9. vutrisiran 25 mg SC every 3 months SC every 3 months (ttr_silencer_sirna, add on) — HELIOS-A (Adams Lancet Neurol 2023 PMID 35262029) — SC dosing convenience
10. daratumumab 1800 mg SC weekly × 8, then biweekly × 16, then monthly (with bortezomib + cyclophosphamide + dex — D-VCd regimen) SC per ANDROMEDA schedule (anti_cd38_monoclonal_antibody, first line) — ANDROMEDA (Kastritis NEJM 2021 PMID 34077641) — daratumumab + CyBorD improved hematologic CR + organ response in AL; AFL component managed simultaneously
11. amiodarone 150 mg IV over 10 min then 1 mg/min × 6 h then 0.5 mg/min × 18 h; 200 mg PO daily maintenance IV/PO load + daily (class_III_AAD, second line) — Most efficacious AAD in structural heart disease; safer than class IC in amyloid; pulm/thyroid/hepatic toxicity monitoring required; ACC/AHA 2024 (PMID 38753446)

Setting playbook (outpatient) — Long-term amyloid + AFL management; lifelong DOAC + tafamidis; periodic disease progression assessment; family screening for ATTRv; routing to typical/atypical AFL variants only if amyloid-specific concerns resolved (rare); cross-link to cardio.acute-hf.amyloidosis.v1 for ADHF episodes — ESC 2023 + ACC/AHA 2024
12. continue lifelong DOAC apixaban 5 mg BID per CHA2DS2-VASc + dose-reduction criteria PO BID — Lifelong stroke prevention in amyloid AFL (ARISTOTLE PMID 21870978; Kittleson 2023 lifelong indication)
13. continue tafamidis 61 mg daily 61 mg PO daily PO daily lifelong — ATTR-CM established (ATTR-ACT (PMID 30145930))
14. wean rate control if successful CTI ablation (rare success in amyloid) taper metoprolol cautiously over 4–8 weeks if no recurrence at 3 mo PO taper — Successful ablation + no recurrence + tolerating taper (ACC/AHA 2024)
15. consider gene-silencer add-on for progression vutrisiran 25 mg SC every 3 months SC q3mo — ATTR progression on tafamidis alone (rising NT-proBNP, declining 6MWD, polyneuropathy) (HELIOS-A (PMID 35262029))

Non-pharmacologic actions:
- Amyloidosis center continuity (tertiary care)
- Cardiac + general rehab maintenance (avoid extreme exertion in restrictive heart)
- Family screening for ATTRv — genetic counseling for first-degree relatives
- LAA occlusion (Watchman) consideration if AC contraindicated long-term — though atrial myopathy makes this less protective
- Vaccinations

AVOID / contraindication checks:
- DIGOXIN ABSOLUTELY CONTRAINDICATED IN CARDIAC AMYLOIDOSIS — binds amyloid fibrils, concentrates in myocardium, narrow toxicity window, multiple case reports of fatal toxicity even at therapeutic levels — ESC 2023 (PMID 37596926); Kittleson 2023 (PMID 37290437)
- Beta blocker CAUTION low dose start in amyloid — autonomic dysfunction + bradyarrhythmia sensitivity + restrictive physiology; ESC 2023
- Non DHP CCB CAUTION in amyloid — also binds amyloid (less than digoxin); negative inotropy worsens restrictive failure; AVOID in HFrEF — ESC 2023
- Flecainide propafenone AVOID with structural heart disease — CAST + applies to amyloid heart
- Dofetilide REMS inpatient init additional caution in amyloid — QT sensitivity
- DOAC renal dose adjustment — ESC 2024 (PMID 39050851)
- Warfarin required if mechanical valve or severe MS — ACC/AHA 2024
- TEE MANDATORY pre cardioversion in amyloid — atrial mechanical dysfunction + LAA thrombus 25–30%
- Catheter ablation lower success in amyloid — diffuse substrate; ~50–60% vs >95% non amyloid CTI; consider before referring
- Diuretic narrow window in amyloid — preload dependent; gentle dosing

Monitoring

Regimen monitoring:
- telemetry continuous during acute — ACC/AHA 2024
- HR target 80-110 in amyloid AVOID bradycardia below 60 — ESC 2023
- daily orthostatic BP during BB or CCB titration — ESC 2023
- serial NT-proBNP + troponin q24-48h for amyloid progression trend
- TEE repeat at 4-6 weeks if AFL persistent for LAA thrombus surveillance
- AL specific FLC weekly during chemotherapy route to hematology
- ATTR specific NT-proBNP + 6MWD + echo at 6 mo on tafamidis
- CBC + eGFR q6m on DOAC — ESC 2024
- LFT TFT PFT baseline then q6m on amiodarone — ACC/AHA 2024
- lifelong AC per amyloid atrial myopathy indication — Kittleson 2023 (PMID 37290437)
- family screening for ATTRv genetic counseling — ESC 2023

Setting (outpatient) monitoring:
- Quarterly amyloidosis + cardiology + hematology (AL) clinic
- Annual TTE; PYP repeat at 2 + 5 yr to track ATTR progression
- CBC + eGFR q6m on DOAC
- LFT + TFT + PFT q6m on amiodarone
- Holter at 6 + 12 mo post-ablation for recurrence
- AL: bone marrow + FLC q6–12 mo per hematology

Follow-up plan: Amyloidosis center referral; cardiology + EP for ablation candidacy assessment (lower success expected); hematology for AL; genetic counseling for ATTRv; lifelong DOAC; tafamidis lifelong for ATTR; periodic echo + NT-proBNP for disease progression
- Close-out criterion: amyloidosis-specific follow-up booked + family screening initiated for ATTRv

Monitoring phase: Telemetry continuous for AFL + arrhythmia + AVN-blocker tolerance; daily orthostasis check; serial NT-proBNP for amyloid trend; AL: monitor FLC weekly during chemotherapy; ATTR: NT-proBNP + 6MWD + echo at 6 mo on tafamidis; LAA thrombus surveillance with repeat TEE in 4–6 weeks if AFL persists

Disposition

Current setting: outpatient — Long-term amyloid + AFL management; lifelong DOAC + tafamidis; periodic disease progression assessment; family screening for ATTRv; routing to typical/atypical AFL variants only if amyloid-specific concerns resolved (rare); cross-link to cardio.acute-hf.amyloidosis.v1 for ADHF episodes — ESC 2023 + ACC/AHA 2024

Disposition criteria:
- Continue chronic surveillance; cross-link to cardio.acute-hf.amyloidosis.v1 if HF decompensation; cross-link to cardio.atrial_flutter.typical-cavotricuspid.v1 if dominant typical morphology and considering ablation despite lower expected success

Escalation triggers (move to higher acuity):
- Recurrent AFL despite ablation → repeat EP — lower expected re-success in amyloid; consider rate control + AC continuation as pragmatic strategy
- New AF after CTI ablation → AF management (cardio.afib.core.v1) — common in amyloid (atrial myopathy)
- Major bleed on AC → reverse + reassess long-term strategy
- Tafamidis ineffective (progression) → add patisiran or vutrisiran
- New advanced AV block → PPM evaluation
- AL FLC rising or new organ involvement → hematology re-induction
- ADHF in amyloid → cardio.acute-hf.amyloidosis.v1 routing

Earlier-Return Triggers

Return-precaution thresholds (watch for):
- [LIFE_THREATENING] Patient with cardiac amyloidosis presenting with new bradyarrhythmia, AV block, GI symptoms, visual disturbance, or altered mental status while on digoxin (often initiated outside facility for AFL rate control without amyloid recognition) — life-threatening iatrogenic emergency
- [LIFE_THREATENING] AL amyloidosis (positive monoclonal screen + biopsy or PYP-negative + cardiac involvement) with rising FLC + cardiac stage III–IV (NT-proBNP >8500 + troponin elevated) presenting with AFL — combined arrhythmic + oncologic emergency
- [LIFE_THREATENING] SBP <90 + lactate >2 + amyloid AFL — restrictive low-output state; usually preload depletion (over-diuresis), AVN-blocker excess, or amyloid CS

Citations

- 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) + ESC 2023 cardiac amyloidosis position statement (PMID 37596926) + Kittleson ACC/AHA 2023 cardiac amyloidosis expert decision pathway (PMID 37290437) [PMID:38753446](https://pubmed.ncbi.nlm.nih.gov/38753446/)
- Cited evidence (PMID 39050851) [PMID:39050851](https://pubmed.ncbi.nlm.nih.gov/39050851/)
- Cited evidence (PMID 37596926) [PMID:37596926](https://pubmed.ncbi.nlm.nih.gov/37596926/)
- Cited evidence (PMID 37290437) [PMID:37290437](https://pubmed.ncbi.nlm.nih.gov/37290437/)
- Cited evidence (PMID 30145930) [PMID:30145930](https://pubmed.ncbi.nlm.nih.gov/30145930/)

Last reconciled with current guidelines: 2026-05-15.
References
  • 2024 ACC/AHA/ACCP/HRS AF + AFL Joint Guideline (Joglar PMID 38753446) + ESC 2023 cardiac amyloidosis position statement (PMID 37596926) + Kittleson ACC/AHA 2023 cardiac amyloidosis expert decision pathway (PMID 37290437) — PMID:38753446
  • Cited evidence (PMID 39050851) — PMID:39050851
  • Cited evidence (PMID 37596926) — PMID:37596926
  • Cited evidence (PMID 37290437) — PMID:37290437
  • Cited evidence (PMID 30145930) — PMID:30145930